2015年3月20日讯 /生物谷BIOON/--据统计，美国医药市场份额2014年是3950亿美元。GlobalData研究和咨询公司对美国医药市场非常看好，预估5年后，也就是2020年，这个数字将会攀升到5480亿美元。
GlobalData的市场分析报告显示，美国医药市场将以年均5.6%的速度增长，驱动其快速增长的因素有哪些呢？归结如下：医疗保健支出越来越多、人口结构老龄化、慢性病比如糖尿病和肥胖的流行、医疗支出报销更便捷以及2010年颁布的《患者保护和大众医疗法》（PPACA）。总结为两点：日趋完善的医疗保障体系和高效可信赖的FDA。
GlobalData医疗行业动态研究部长Joshua Owide说：“《患者保护和大众医疗法》和其附件《医疗和教育纠纷调解条例》对美国市民的影响是长久而深远的，对制药工业同样如此。PPACA的颁布意味着医疗保险普及面更广，越来越多的人新参保或者更改保险方案争取到了更多补贴。2013年处方药市场只有2620亿美元，2014年增加到了2759亿美元。据统计，大约有3200万市民是新参保的，这就会在10年之间产生至少1150亿美元的医疗消费。”
另外，FDA“高效透明、结构化的监管体系”也促进了新药的快速审批和质量保证，这也是医药市场如此繁荣的原因之一。FDA采取了一系列有利于医药制造商的举措。FDA设立的“绿色通道”和“重大突破专门通道”加速了新药的审批，也让一些突破性药物更快上市。2014年，FDA审批了41种新药，其中有17种是治疗罕见病的。同时，美国完善的专利体系也推动了医药制造商向研究型企业的转变，这也加速了新药的开发。
英文原文：US pharma market to reach $550bn by 2020
Health reforms and the new FDA initiatives among the factors that will help it grow
The US pharmaceutical market is forecast to jump in value from $395bn in 2014 to $548bn by the end of the decade， according to research and consulting firm GlobalData.
The company's latest report finds that this is a Compound Annual Growth Rate (CAGR) of 5.6%， and will be driven by a number of factors.
These include increased healthcare expenditure， an ageing population， the rising prevalence of chronic lifestyle diseases such as diabetes and obesity， universal and easy access to reimbursement for pharmaceutical product costs， and the 2010 Patient Protection and Affordable Care Act (PPACA).
Joshua Owide， GlobalData's director of healthcare industry dynamics， explained that the PPACA and its amendment， the Health Care and Education Reconciliation Act， continue to have a “substantial impact” on US citizens， and the country's pharmaceutical industry.
Owide said： “As the PPACA mandates health insurance coverage for all Americans， the US has witnessed increasing use of prescription drugs among individuals who are newly insured or have shifted to insurance plans that offer premium and cost-sharing subsidies. In 2014， spending on prescription drugs amounted to an estimated $275.9bn， compared with $262.3bn in 2013.
“Around 20 provisions of the healthcare legislation are expected to have a direct or indirect impact on the volume of drug and biologic sales. As many as 32 million formerly uninsured citizens could enter the patient pool， resulting in new business worth $115bn over a period of 10 years.”
GlobalData's report also notes that the FDA's “transparent， well-structured and competent regulatory system” that facilitates the approval of pharmaceutical products is also consequently bolstering market growth.
Owide continued： “New initiatives undertaken by the FDA to strengthen the review and approval process will be advantageous to the industry. Its strong patent system attracts research-based pharmaceutical companies and positively influences growth.
“In 2014， 41 novel drugs were approved by the FDA， 17 of which were for the treatment of rare diseases. Schemes such as the FDA's 'Fast Track Development Program' and 'Breakthrough Designation' accelerate the approval of novel drugs and add value to the market by meeting demand more quickly.”